Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Experimental and Applied Biomedical Research (EABR)
Volume 23 (2022): Issue 2 (June 2022)
Open Access
The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It?
Dejan Simic
Dejan Simic
,
Aleksandar Spasic
Aleksandar Spasic
,
Mirko Jovanovic
Mirko Jovanovic
,
Predrag Maric
Predrag Maric
,
Radovan Milosevic
Radovan Milosevic
and
Ivan Srejovic
Ivan Srejovic
| Jul 11, 2022
Experimental and Applied Biomedical Research (EABR)
Volume 23 (2022): Issue 2 (June 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Jul 11, 2022
Page range:
175 - 184
Received:
Dec 19, 2017
Accepted:
Dec 28, 2017
DOI:
https://doi.org/10.1515/sjecr-2017-0073
Keywords
Phosphodiesterase-5 inhibitors
,
Prostate carcinoma
,
Sildenafil
,
Tadalafil
© 2019 Dejan Simic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.